SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations…

Evaxion · PRESS-RELEASE filed Aug 20, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 20, 2026 at 07:30 ET

Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year ago, with cash of $14.0M funding operations into H2 2027. The company highlighted pipeline progress including upcoming ESMO data for EVX-01 and preclinical advances for EVX-04 and EVX-05, but reported zero revenue and a GAAP EPS of -$0.01, which was a 4900% miss vs the -$0.01 consensus estimate due to a rounding artifact on a tiny base. The filing is neutral as the financials were as expected and the EPS miss is mechanical on a pre-revenue biotech with minimal analyst coverage, while pipeline catalysts are forward-looking and uncertain.

  • Q2 2026 net loss of $3.7M vs $4.8M in Q2 2025, in line with expectations
  • Cash and cash equivalents of $14.0M as of June 30, 2026, providing runway into H2 2027
  • R&D expenses of $2.3M, G&A of $1.5M, both aligned with Q1 2026
  • Zero revenue reported; GAAP EPS of -$0.01 vs consensus of -$0.01 (miss of -4900% is a mechanical artifact of a tiny base)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access